Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants

NCT05260437 PHASE1 COMPLETED Results posted

Prevention of COVID-19 caused by SARS-CoV-2.

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE1
Status	COMPLETED
Enrolment	99
Start date	Thu Mar 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• COVID-19
• SARS-CoV-2

Interventions

• CV2CoV (2 µg)
• CV2CoV (4 µg)
• CV2CoV (8 µg)
• CV2CoV (12 µg)
• CV2CoV (16 µg)
• CV2CoV (20 µg)

Countries

United States